A Pilot Open-label Study to Assess the Efficacy and Safety of Tocilizumab in Patients With Active Schnitzler's Syndrome
Phase of Trial: Phase II
Latest Information Update: 24 Sep 2019
Price : $35 *
At a glance
- Drugs Tocilizumab (Primary)
- Indications Schnitzler syndrome
- Focus Therapeutic Use
- Acronyms TOCISCH
- 24 Sep 2019 Status changed from recruiting to completed.
- 19 Jul 2017 Status changed from not yet recruiting to recruiting.
- 10 Feb 2017 New trial record